Back to search

Article

Pre-exposure prophylaxis for COVID-19 with Tix-agevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center Experience

2023-10-02

Abstract excerpt

Pre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab in immunocompromised patients has reduced the risk of breakthrough infection, disease, hospitalization, and COVID-19 related mortality. However, the advent of the Kraken variant (XBB.1.5) has limited the use of this monoclonal antibody, based on poor efficacy in in vitro studies The objective of the study was to evaluate the risk of breakthrough inf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6e66f525-611f-5e02-ab11-7abfbfd25e21
DOI
10.20944/preprints202309.2171.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pre-exposure prophylaxis for COVID-19 with Tix-agevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center ExperienceDOI 10.20944/preprints202309.2171.v1
Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (Evusheld™) prophylaxis in kidney transplant recipientsSemantic proximity
Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19Semantic proximity
Long-term outcomes and neutralising antibody kinetics after Tixagevimab/Cilgavimab prophylaxis in haematological patients: a real-world cohort study in JapanSemantic proximity
Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patientsSemantic proximity
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 TrialSemantic proximity
Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patientsSemantic proximity
Evaluation of neutralizing capacity of tixagevimab plus cilgavimab: a case-series study with comparison to a vaccinated populationSemantic proximity
COVID-19 Outcomes in Kidney Transplant Recipients in a German Transplant CenterSemantic proximity
Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron EraSemantic proximity
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic DataSemantic proximity
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipientsSemantic proximity
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialSemantic proximity
Select a neighboring publication to make it the new centre.